GuruFocus Premium Membership

Serving Intelligent Investors since 2004. Only 96 cents a day.

Free Trial

Free 7-day Trial
All Articles and Columns »

Vanguard Health Care Fund Buys Abbott Laboratories, Merck, Gilead Sciences, Sells Vertex Pharmaceuticals, Dean Foods

May 05, 2011 | About:
10qk

Vanguard Health Care Fund is managed by Edward Owens, which is arguably the best fund manager in the health care industry. The fund has outperformed its benchmark Spliced Health Care Index in all periods. It averaged 7.17% annually in the past 10 years while the index just averaged 1.65%.

Edward Owens buys Abbott Laboratories, Merck & Co. Inc., Gilead Sciences Inc., Alcon, sells Genzyme Corp., Vertex Pharmaceuticals Inc., Dean Foods Co. during the 3-months ended 03/31/2011, according to the most recent filings of his investment company, Vanguard Health Care Fund. As of 03/31/2011, Vanguard Health Care Fund owns 79 stocks with a total value of $18.8 billion. These are the details of the buys and sells.

This is the portfolio chart of Edward Owens. You can click on the legend of the chart to show/hide buys, sells or holdings. Each ball on the chart represents a position in the portfolio. You can move your mouse on the balls to see the details of each position and click to see the details of all guru trades with this position.



For the details of Edward Owens's stock buys and sells, go to http://www.gurufocus.com/StockBuy.php?GuruName=Edward+Owens

This is the sector weightings of his portfolio:

Health Care 64.4%
Consumer Services 8.1%
Technology 1.7%
Basic Materials 0.7%
Industrials 0.7%
Financials 0.5%


These are the top 5 holdings of Edward Owens

  1. MERCK & CO. INC. (MRK) - 34,030,248 shares, 5.97% of the total portfolio. Shares added by 3.97%
  2. PFIZER INC. (PFE) - 43,059,788 shares, 4.65% of the total portfolio. Shares reduced by 1.15%
  3. FOREST LABORATORIES INC. (FRX) - 26,803,000 shares, 4.6% of the total portfolio. Shares reduced by 5.47%
  4. UNITEDHEALTH GROUP Inc. (UNH) - 18,685,100 shares, 4.49% of the total portfolio. Shares reduced by 0.53%
  5. MCKESSON Corp. (MCK) - 9,889,900 shares, 4.15% of the total portfolio. Shares reduced by 6.61%


Added: Abbott Laboratories (ABT)

Edward Owens added to his holdings in Abbott Laboratories by 9.09%. His purchase prices were between $45.16 and $49.07, with an estimated average price of $47.36. The impact to his portfolio due to this purchase was 0.31%. His holdings were 14,400,000 shares as of 03/31/2011.

Abbott Laboratories is a global, broad-based health care company devoted to discovering new medicines, new technologies and new ways to manage health. Abbott Laboratories has a market cap of $81.93 billion; its shares were traded at around $52.94 with a P/E ratio of 12.4 and P/S ratio of 2.3. The dividend yield of Abbott Laboratories stocks is 3.6%. Abbott Laboratories had an annual average earnings growth of 7.8% over the past 10 years. GuruFocus rated Abbott Laboratories the business predictability rank of 5-star.

Added: Merck & Co. Inc. (MRK)

Edward Owens added to his holdings in Merck & Co. Inc. by 3.97%. His purchase prices were between $31.08 and $37.35, with an estimated average price of $33.55. The impact to his portfolio due to this purchase was 0.23%. His holdings were 34,030,248 shares as of 03/31/2011.

Merck & Co., Inc. is a global research-driven pharmaceutical company dedicated to putting patients first. Merck & Co. Inc. has a market cap of $112.72 billion; its shares were traded at around $36.56 with a P/E ratio of 10.4 and P/S ratio of 2.4. The dividend yield of Merck & Co. Inc. stocks is 4.2%.

Added: Gilead Sciences Inc. (GILD)

Edward Owens added to his holdings in Gilead Sciences Inc. by 8.69%. His purchase prices were between $36.24 and $42.51, with an estimated average price of $39.15. The impact to his portfolio due to this purchase was 0.14%. His holdings were 7,507,100 shares as of 03/31/2011.

Gilead Sciences, Inc. is an independent biopharmaceutical company that seeks to provide accelerated solutions for patients and the people who care for them. Gilead Sciences Inc. has a market cap of $32.77 billion; its shares were traded at around $41.33 with a P/E ratio of 12.2 and P/S ratio of 4.5. Gilead Sciences Inc. had an annual average earnings growth of 44.8% over the past 5 years.

Reduced: Vertex Pharmaceuticals Inc. (VRTX)

Edward Owens reduced to his holdings in Vertex Pharmaceuticals Inc. by 22.87%. His sale prices were between $35.03 and $51.07, with an estimated average price of $41.71. The impact to his portfolio due to this sale was -0.23%. Edward Owens still held 3,002,800 shares as of 03/31/2011.

Vertex Pharmaceuticals Inc. discovers, develops and markets small molecule drugs that address major unmet medical needs. Vertex Pharmaceuticals Inc. has a market cap of $11.31 billion; its shares were traded at around $55.31 with and P/S ratio of 78.9. Vertex Pharmaceuticals Inc. had an annual average earnings growth of 13.3% over the past 10 years.

Sold Out: Dean Foods Co. (DF)

Edward Owens sold out his holdings in Dean Foods Co.. His sale prices were between $8.66 and $10.56, with an estimated average price of $10.

Dean Foods Company is the nation's processor and distributor of fresh milk and other dairy products, and a leader in the specialty foods industry. Dean Foods Co. has a market cap of $2.03 billion; its shares were traded at around $11.11 with a P/E ratio of 13.7 and P/S ratio of 0.2.


Rating: 2.3/5 (7 votes)

Comments

Please leave your comment:


Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK